Primary angioplasty

NEW YORK, June 14 (Praxis Press) Rapid reperfusion after acute myocardial infarction (MI) using thrombolytic therapy reduces mortality, but whether time to primary angioplasty is also related to mortality is unclear. Investigators examined 27,080 patients with acute MI associated with ST-segment elevation or left bundle-branch block who were treated with angioplasty (see paper). Cannon and colleagues found that the odds of in-hospital mortality increased from 41% to 62% when the time to primary

| 1 min read

Register for free to listen to this article
Listen with Speechify
0:00
1:00
Share

NEW YORK, June 14 (Praxis Press) Rapid reperfusion after acute myocardial infarction (MI) using thrombolytic therapy reduces mortality, but whether time to primary angioplasty is also related to mortality is unclear. Investigators examined 27,080 patients with acute MI associated with ST-segment elevation or left bundle-branch block who were treated with angioplasty (see paper). Cannon and colleagues found that the odds of in-hospital mortality increased from 41% to 62% when the time to primary angioplasty was more than 2 hours after the patient had arrived at the hospital. Increasing delay from symptom onset to primary angioplasty, however, was not associated with a significant increase in in-hospital mortality. Minimizing the time from patient arrival to primary angioplasty reduces patient mortality.

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to more than 35 years of archives, as well as TS Digest, digital editions of The Scientist, feature stories, and much more!
Already a member? Login Here
Share
Illustration of a developing fetus surrounded by a clear fluid with a subtle yellow tinge, representing amniotic fluid.
January 2026

What Is the Amniotic Fluid Composed of?

The liquid world of fetal development provides a rich source of nutrition and protection tailored to meet the needs of the growing fetus.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies

Parse Logo

Parse Biosciences and Graph Therapeutics Partner to Build Large Functional Immune Perturbation Atlas

Sino Biological Logo

Sino Biological's Launch of SwiftFluo® TR-FRET Kits Pioneers a New Era in High-Throughout Kinase Inhibitor Screening

SPT Labtech Logo

SPT Labtech enables automated Twist Bioscience NGS library preparation workflows on SPT's firefly platform